Predictors of response to lenalidomide in a non-del(5q) MDS patient

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/56/f2/b8/56f2b88c-f71b-11ca-2fa0-ecddc1044fe8/mza_2145894122309428224.jpg/600x600bb.jpg

MediCom Oncology Clinical Pearls Podcasts

MediCom Oncology

53 episodes

1 month ago

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

RSS

All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

https://i1.sndcdn.com/artworks-000280782725-5s1zli-t3000x3000.jpg

Predictors of response to lenalidomide in a non-del(5q) MDS patient

MediCom Oncology Clinical Pearls Podcasts

3 minutes 3 seconds

7 years ago

Predictors of response to lenalidomide in a non-del(5q) MDS patient

Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.